StreetInsider.com News Articles

Continuous Glucose Monitoring on the Rise Among Medicare Advantage Members with Type 2 Diabetes

Thu, 12 Mar 2026 09:30:00 -0400

Study by Humana Healthcare Research and Yale School of Medicine researcher reveals significant increase in CGM usage, particularly among older adults with chronic health conditions.

LOUISVILLE, Ky.--(BUSINESS WIRE)-- A new study published in the current issue of the Journal of Managed Care & Specialty Pharmacy (JMCP)—conducted by a Humana Healthcare Research team and Dr. Joseph S. Ross of the Yale School of Medicine—reveals a notable increase in the use of continuous glucose monitors (CGMs) among Medicare Advantage members with type 2 diabetes from 2021 to 2023.

The study also compared the

Continuous Glucose Monitoring on the Rise Among Medicare Advantage Members with Type 2 Diabetes

Thu, 12 Mar 2026 09:30:00 -0400

Study by Humana Healthcare Research and Yale School of Medicine researcher reveals significant increase in CGM usage, particularly among older adults with chronic health conditions.

The study also compared the

Continuous Glucose Monitoring on the Rise Among Medicare Advantage Members with Type 2 Diabetes

Thu, 12 Mar 2026 09:30:00 -0400

Study by Humana Healthcare Research and Yale School of Medicine researcher reveals significant increase in CGM usage, particularly among older adults with chronic health conditions.

The study also compared the

Continuous Glucose Monitoring on the Rise Among Medicare Advantage Members with Type 2 Diabetes

Thu, 12 Mar 2026 09:30:00 -0400

Study by Humana Healthcare Research and Yale School of Medicine researcher reveals significant increase in CGM usage, particularly among older adults with chronic health conditions.

The study also compared the

Humana (HUM) PT Lowered to $182 at Piper Sandler

Wed, 11 Mar 2026 06:19:31 -0400

Piper Sandler analyst Jessica Tassan lowered the price target on Humana (NYSE: HUM) to $182.00 (from $265.00) while maintaining a Neutral rating.

The analyst comments "We update our model to more closely conform with CY26 consensus estimates and guidance. Our CY27 and CY28 estimates assume LSD MA rates (see note here), 200-300 bps of risk adjustment yield per year, minimal benefit cuts to preserve margins, and normalized trend vs. CY25/ CY26 highs. If HUM can achieve ~75.0% of MA members in 4-Star or better contracts for CY28 bonus year, we estimate that CY28 Quality Bonus Payments could yield up to ~120

Humana (HUM) PT Lowered to $182 at Piper Sandler

Wed, 11 Mar 2026 06:19:31 -0400

Piper Sandler analyst Jessica Tassan lowered the price target on Humana (NYSE: HUM) to $182.00 (from $265.00) while maintaining a Neutral rating.

Humana completes $1 billion junior subordinated notes offering

Mon, 09 Mar 2026 17:05:54 -0400

Humana Inc. (NYSE: HUM) completed a public offering of $1 billion in aggregate principal amount of fixed-to-fixed rate junior subordinated notes due 2056, the health insurer announced.

The notes carry an interest rate of 6.625 percent of the principal amount. The company expects net proceeds of approximately $986 million after deducting underwriters' discounts and estimated offering expenses.

Humana plans to use the net proceeds for general corporate purposes, which may include repaying existing debt, including borrowings under its commercial paper program.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Mizuho Securities USA LLC, Truist Securities, Inc. and Wells Fargo Securities, LLC served

Humana Completes Aggregate $1.0 Billion Fixed-to-Fixed Rate Junior Subordinated Notes Offering